Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.

de Vries AC, Stam RW, Schneider P, Niemeyer CM, van Wering ER, Haas OA, Kratz CP, den Boer ML, Pieters R, van den Heuvel-Eibrink MM.

Haematologica. 2007 Nov;92(11):1557-60.

2.

[Possibility of targeting FLT3 kinase for the treatment of leukemia].

Kiyoi H.

Rinsho Ketsueki. 2005 Mar;46(3):187-97. Review. Japanese. No abstract available.

PMID:
16447713
3.

[FLT3 kinase inhibitors for the treatment of acute leukemia].

Kiyoi H.

Rinsho Ketsueki. 2010 Jun;51(6):384-9. Review. Japanese. No abstract available.

PMID:
20622483
4.

FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.

Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM.

Stem Cells. 2006 May;24(5):1174-84. Epub 2006 Jan 12. Review.

5.

FLT3 inhibitors for the treatment of acute myeloid leukemia.

Wiernik PH.

Clin Adv Hematol Oncol. 2010 Jun;8(6):429-36, 444. Review.

PMID:
20733555
6.

Mutant FLT3 signaling contributes to a block in myeloid differentiation.

Zheng R, Small D.

Leuk Lymphoma. 2005 Dec;46(12):1679-87. Review.

PMID:
16263569
7.

Implications of FLT3 mutations in the therapy of acute myeloid leukemia.

Mattison RJ, Ostler KR, Locke FL, Godley LA.

Rev Recent Clin Trials. 2007 May;2(2):135-41. Review.

PMID:
18473998
8.
9.

Structural and functional alterations of FLT3 in acute myeloid leukemia.

Meshinchi S, Appelbaum FR.

Clin Cancer Res. 2009 Jul 1;15(13):4263-9. doi: 10.1158/1078-0432.CCR-08-1123. Epub 2009 Jun 23. Review.

10.

Emerging Flt3 kinase inhibitors in the treatment of leukaemia.

Tickenbrock L, Müller-Tidow C, Berdel WE, Serve H.

Expert Opin Emerg Drugs. 2006 Mar;11(1):153-65. Review.

PMID:
16503833

Supplemental Content

Support Center